Cystic Fibrosis

September 28, 2016September 28, 2016

Specific Mold Toxins Weaken Airways’ Defenses and Immunity, Penn Study Shows

COPD, Cystic Fibrosis, News

Researchers at the Perelman School of Medicine at the University of Pennsylvania found that toxins from a type of mold, called aflatoxins, weaken the airways’ self-clearing mechanisms and immunity, which may ... Read more

August 22, 2016August 22, 2016

FDA Grants Orphan Drug Status to Pulmatrix’s PUR1900 for Cystic Fibrosis Fungal Lung Infections

Cystic Fibrosis, News

The U.S. Food & Drug Administration (FDA) has granted orphan drug designation to Pulmatrix‘s PUR1900, an inhaled drug for the treatment of pulmonary fungal infections in patients with cystic fibrosis (CF). ... Read more

August 11, 2016August 11, 2016

New Lung Disease Scanning Technology Has Potential to Transform Standard Treatment

Cystic Fibrosis, News

A new lung scanning technology with the potential to transform the treatment of people suffering from lung disease was developed by researchers at Monash University in Australia. The four-dimensional lung scanning platform ... Read more

July 21, 2016July 21, 2016

FDA Grants Fast Track Status to Cystic Fibrosis Therapy QR-010 by ProQR

Cystic Fibrosis, News

ProQR Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its molecule QR-010 for the treatment of cystic fibrosis (CF) patients who have the deltaF508 mutation in ... Read more

July 21, 2016July 21, 2016

Savara Builds on Serendex Acquisition by Advancing Inhaled Therapies for Lung Diseases, Infections

Cystic Fibrosis, News

Savara Pharmaceuticals of Austin, Texas, this week announced that it has fully acquired Serendex Pharmaceuticals, a Danish company, adding to its pipeline of specialty products to treat rare respiratory diseases, and noting three candidates in its drug portfolio ... Read more

July 18, 2016July 18, 2016

Enrollment Complete in Clinical Trial of Bronchitol for Cystic Fibrosis

Cystic Fibrosis, News

Pharmaxis has reached its targeted enrollment in its international clinical trial (CF303) evaluating Bronchitol (mannitol) in cystic fibrosis (CF) patients. The Australian pharmaceutical company expects results by the middle of 2017. ... Read more

July 14, 2016July 14, 2016

ProterixBio Appoints Pulmonary Disease Expert to Scientific Advisory Board

COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

ProterixBio (formerly BioScale) appointed Dr. Fernando Martinez, MD, to its scientific and medical advisory board. The Massachusetts-based company says the addition of Martinez, a global clinical expert in pulmonary diseases such ... Read more

July 13, 2016July 13, 2016

Vertex, Moderna Collaborate on mRNA Therapeutics for CF Treatment

Cystic Fibrosis, News

Vertex Pharmaceuticals and Moderna Therapeutics recently announced an exclusive research collaboration and licensing agreement to discover and develop the messenger ribonucleic acid trademarked (mRNA) Therapeutics for the treatment of cystic fibrosis (CF). Vertex ... Read more

July 11, 2016July 11, 2016

Viruses Likely Help Bacteria Become Worse in Cystic Fibrosis Lungs

Cystic Fibrosis, News

Bacteriophages (viruses that infect bacteria) may help common bacteria to better adapt to the lungs of cystic fibrosis (CF) patients, making them more difficult to clear, new study shows. This ... Read more

July 8, 2016July 8, 2016

Nivalis Completes Enrollment in Phase 2 Study of Cystic Fibrosis Therapy

Cystic Fibrosis, News

Nivalis Therapeutics has enrolled the last patient in the larger of two Phase 2 clinical trials evaluating the company’s lead clinical candidate, N91115, for the treatment of cystic fibrosis patients with two faulty copies ... Read more